Search

Mitchell G Brigell

from Belmont, MA
Age ~73
Get Report
Also known as:
Mitchell Deborah Brigell, Mitchell Debora Brigell, Mitchel Brigell, George Brigell Mitchell
Phone and address:
530 Pleasant St, Belmont, MA 02478
(617) 932-1181
Related to:
Sara Weiss
Connected to:
Linda Brigg, 81Scott W Briggance, 61Sarah L Brigge, 34Peter F Briggeman, 67Chris Brigger, 59Stephanie K Brigger, 65Kelly A Briggette, 52Johnny L Briggins, 68Laura Briggin, 70Mary Briggins, 68

Mitchell Brigell Phones & Addresses

  • 530 Pleasant St, Belmont, MA 02478 (617) 932-1181
  • Gloucester, MA
  • Ann Arbor, MI
  • Cambridge, MA
  • Oak Park, IL
  • Chicago, IL

Work

Company: Aerpio therapeutics Aug 2013 to Jan 2015 Position: Director of cinical research, ophthalmology

Education

School / High School: Northeastern University 1977 to 1980 Specialities: Neuroscience

Skills

Clinical Development • Clinical Study Design • Ophthalmology • Clinical Trials • Drug Development • Diabetic Retinopathy • Clinical Research • Neuroscience • Macular Degeneration • Vision Science • Translational Medicine • Pharmaceutical Industry • Evoked Potentials • Investigator Brochures • Biotechnology • Gcp

Industries

Pharmaceuticals

Resumes

Resumes

Mitchell Brigell Photo 1

Consultant

View page
Location:
530 Pleasant St, Belmont, MA 02478
Industry:
Pharmaceuticals
Work:
Aerpio Therapeutics Aug 2013 - Jan 2015
Director of Cinical Research, Ophthalmology
Aerpio Therapeutics Aug 2013 - Jan 2015
Vice President of Clinical Development
Novartis 2007 - Aug 2013
Executive Director - Translational Medicine, Ophthalmology
Pfizer Feb 1999 - Aug 2007
Senior Director
Pgrd 1999 - 2007
Senior Director
Education:
Northeastern University 1977 - 1980
Kansas State University 1972 - 1977
Doctorates, Doctor of Philosophy, Psychology Stony Brook University 1968 - 1972
Bachelors, Bachelor of Arts, Psychology
Skills:
Clinical Development
Clinical Study Design
Ophthalmology
Clinical Trials
Drug Development
Diabetic Retinopathy
Clinical Research
Neuroscience
Macular Degeneration
Vision Science
Translational Medicine
Pharmaceutical Industry
Evoked Potentials
Investigator Brochures
Biotechnology
Gcp

Publications

Us Patents

Dosing Regimes For The Treatment Of Ocular Vascular Disease

View page
US Patent:
20130197016, Aug 1, 2013
Filed:
Oct 25, 2011
Appl. No.:
13/878678
Inventors:
Mitchell Brigell - Belmont MA, US
Peter End - Oberwil, CH
Vinayak Hosagrahara - Chembur, IN
Bruce D. Jaffee - Hopkinton MA, US
Erik Meredith - Hudson MA, US
Ronald Keith Newton - Hanover MA, US
Stephen Poor - Winthrop MA, US
Yubin Qiu - Newton MA, US
International Classification:
A61K 31/506
A61K 31/44
A61K 31/505
A61K 31/519
A61K 31/4709
US Classification:
5142641, 514275, 514269, 514312, 5142651, 514350
Abstract:
The use of vascular endothelial growth factor receptor 2 inhibitors or a pharmaceutically acceptable salt thereof for the treatment of ocular vascular disease is provided. Dosing regimes, including once weekly administration, of certain VEGF-R2 inhibitors are provided which deliver therapeutically effective concentrations of the VEGF-R2 compounds in ocular tissues for at least one week for the treatment of ocular vascular disease.

Methods Of Treating Diabetic Nephropathy Using Hptpb Inhibitors

View page
US Patent:
20190262321, Aug 29, 2019
Filed:
Feb 25, 2019
Appl. No.:
16/284349
Inventors:
- Cincinnati OH, US
Mitchell BRIGELL - Belmont MA, US
Stephen PAKOLA - Irvington NY, US
Robert Shalwitz - Bexley OH, US
International Classification:
A61K 31/427
A61P 3/00
A61K 31/16
A61P 13/12
A61K 31/137
Abstract:
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with diabetic nephropathy, for example, diabetic nephropathy resulting from hyperglycemia, kidney hyperfiltration, renal injury, glycation products, and cytokine activation.
Control profile
Mitchell G Brigell from Belmont, MA, age ~73 Get Report